EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia

Samara Griffin iD, Jason Asselin iD, Anna Lee Wilkinson, Michael W Traeger, Alisa Pedrana iD, Rebecca J Winter, Alexander J Thompson, Matthew Penn, Wayne Dimech, Basil Donovan iD, Margaret Hellard, Mark Stoové

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Samara Griffin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Disease Elimination, Burnet Institute, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Hepatitis C, Opiate Substitution Treatment, Analgesics, Opioid, Opioid-Related Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Blood Borne Virus & STI Research, Intervention and Strategic Evaluation Program, New South Wales Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People prescribed opioid agonist therapy (OAT) are a key population for hepatitis C virus (HCV) elimination. Health service engagement associated with OAT provision may facilitate hepatitis C testing and treatment. We aimed to quantify the HCV care cascade among people receiving OAT in Australia.

Methods

We extracted linked data from individuals attending any of 58 clinics participating in the ACCESS national sentinel surveillance network of primary care and sexual health clinics from 1 January 2016 to 31 December 2023. Outcomes included evidence of any HCV test (antibody or RNA) or direct-acting antiviral (DAA) prescription at an ACCESS clinic after their first OAT prescription. RNA positive individuals were inferred antibody positive; individuals with a DAA prescription were inferred RNA and antibody positive. We determined the number of individuals at each stage of the following cascade by the end of the study period: (1) positive antibody, (2) positive RNA, and (3) DAA prescription.

Results

Among 15 382 individuals prescribed OAT, 44% (6817) had an HCV antibody or RNA test after their first OAT prescription. Of these, 64% (4368/6817) were antibody positive by the end of the study period. Of these, 67% (2911/4368) were RNA positive, and of those, 69% (2007/2911) were prescribed DAAs.

Conclusions

A high proportion of people prescribed OAT were not engaged in care by their OAT provider or across ACCESS network clinics, but when diagnosed, rates of treatment were high. Given high HCV antibody and RNA prevalence, integrating HCV care into regular OAT care should be a priority for HCV elimination in Australia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis COpiate Substitution TreatmentAnalgesics, OpioidOpioid-Related DisordersHumansAustraliaMaleFemaleAntiviral AgentsMiddle AgedAdultHepacivirusHepatitis C AntibodiesYoung AdultRNA, Viral

Stichwörter der Autor:innen

blood-borne virusescascade of carehepatitis C virusopioid agonist therapyprimary care

Substanzen

Antiviral AgentsAnalgesics, OpioidHepatitis C AntibodiesRNA, Viral

Autor:innen und Institutionen

  • Disease Elimination, Burnet Institute, Melbourne, Victoria, Australia.
  • School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
  • North Richmond Community Health, Melbourne, Victoria, Australia.

ORCID-Profile: Samara Griffin, Jason Asselin, Alisa Pedrana, Basil Donovan

Förderung

  • Blood Borne Virus & STI Research, Intervention and Strategic Evaluation Program
  • New South Wales Ministry of Health

Zitieren

APA

Griffin, S., Asselin, J., Wilkinson, A. L., Traeger, M. W., Pedrana, A., Winter, R. J., Thompson, A. J., Penn, M., Dimech, W., Donovan, B., Hellard, M., & Stoové, M. (2025). The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf352

Vancouver

Griffin S, Asselin J, Wilkinson AL, Traeger MW, Pedrana A, Winter RJ, et al. The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf352

BibTeX
@article{Griffin2025,
  author = {Griffin, Samara and Asselin, Jason and Wilkinson, Anna Lee and Traeger, Michael W and Pedrana, Alisa and Winter, Rebecca J and Thompson, Alexander J and Penn, Matthew and Dimech, Wayne and Donovan, Basil and Hellard, Margaret and Stoové, Mark},
  title = {The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf352}
}
Kostenlos starten →